SEC Form 4 · accession 0001187443-26-000010
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur F Ryan
Director
Period of report
Jul 2, 2026
Accepted (ET)
Jul 7, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jul 2, 2026 | S | 200 | $650.15 | D | 17,303 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
- F2Represents volume-weighted average price of sales of 200 shares of Company stock on July 2, 2026 at prices ranging from $650.10 to $650.19. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 2, 2026 at each separate price.